Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

Cell surface membrane proteins as personalized biomarkers: where we stand and where we are headed.

Várady G, Cserepes J, Németh A, Szabó E, Sarkadi B.

Biomark Med. 2013 Oct;7(5):803-19. doi: 10.2217/bmm.13.90. Review.

PMID:
24044572
2.

Protein microarrays for personalized medicine.

Yu X, Schneiderhan-Marra N, Joos TO.

Clin Chem. 2010 Mar;56(3):376-87. doi: 10.1373/clinchem.2009.137158. Review.

3.

Profiling protein expression and interactions: proximity ligation as a tool for personalized medicine.

Blokzijl A, Friedman M, Pontén F, Landegren U.

J Intern Med. 2010 Sep;268(3):232-45. doi: 10.1111/j.1365-2796.2010.02256.x. Review.

4.

Personalized oncology: recent advances and future challenges.

Kalia M.

Metabolism. 2013 Jan;62 Suppl 1:S11-4. doi: 10.1016/j.metabol.2012.08.016. Review.

PMID:
22999010
5.

Advances in membrane proteomics and cancer biomarker discovery: current status and future perspective.

Shukla HD, Vaitiekunas P, Cotter RJ.

Proteomics. 2012 Oct;12(19-20):3085-104. doi: 10.1002/pmic.201100519. Review.

PMID:
22890602
6.

Application of proteomic technologies for prostate cancer detection, prognosis, and tailored therapy.

Fredolini C, Liotta LA, Petricoin EF.

Crit Rev Clin Lab Sci. 2010 May-Jun;47(3):125-38. doi: 10.3109/10408363.2010.503558. Review.

PMID:
20858067
7.

Membrane proteomics: the development of diagnostics based on protein shedding.

Lai ZW, Steer DL, Smith AI.

Curr Opin Mol Ther. 2009 Dec;11(6):623-31. Review.

PMID:
20072939
8.

[Protein microarrays and personalized medicine].

Yu X, Schneiderhan-Marra N, Joos TO.

Ann Biol Clin (Paris). 2011 Jan-Feb;69(1):17-29. doi: 10.1684/abc.2010.0512. Review. French.

9.

Innovative diagnostic technologies and their significance for personalized medicine.

Jain KK.

Mol Diagn Ther. 2010 Jun 1;14(3):141-7. doi: 10.2165/11536240-000000000-00000.

PMID:
20560675
10.

Alterations of membrane protein expression in red blood cells of Alzheimer's disease patients.

Várady G, Szabó E, Fehér Á, Németh A, Zámbó B, Pákáski M, Janka Z, Sarkadi B.

Alzheimers Dement (Amst). 2015 Jul 21;1(3):334-8. doi: 10.1016/j.dadm.2015.06.007.

11.

Cell surface biomarkers of embryonic stem cells.

Nagano K, Yoshida Y, Isobe T.

Proteomics. 2008 Oct;8(19):4025-35. doi: 10.1002/pmic.200800073. Review.

PMID:
18763704
12.

Translational implications of inflammatory biomarkers and cytokine networks in psychoneuroimmunology.

Yan Q.

Methods Mol Biol. 2012;934:105-20. doi: 10.1007/978-1-62703-071-7_6.

PMID:
22933143
13.

Biomarkers for multiple sclerosis.

Villoslada P.

Drug News Perspect. 2010 Nov;23(9):585-95. doi: 10.1358/dnp.2010.23.9.1472300. Review.

PMID:
21152453
14.

Biomarkers in rare diseases.

Ferlini A, Scotton C, Novelli G.

Public Health Genomics. 2013;16(6):313-21. doi: 10.1159/000355938. Review.

PMID:
24503592
15.

Cooperation of liver cells in health and disease.

Kmieć Z.

Adv Anat Embryol Cell Biol. 2001;161:III-XIII, 1-151. Review.

PMID:
11729749
16.

[Biomarkers and personalized medicine].

Scherer HU, Burmester GR, Häupl T.

Z Rheumatol. 2013 Feb;72(1):20-6. doi: 10.1007/s00393-011-0884-5. German.

PMID:
23223890
17.

Clinical proteomics: from biomarker discovery and cell signaling profiles to individualized personal therapy.

Calvo KR, Liotta LA, Petricoin EF.

Biosci Rep. 2005 Feb-Apr;25(1-2):107-25. Review.

PMID:
16222423
18.

Epigenetic profiling joins personalized cancer medicine.

Heyn H, Méndez-González J, Esteller M.

Expert Rev Mol Diagn. 2013 Jun;13(5):473-9. doi: 10.1586/erm.13.36. Review.

PMID:
23782254
19.

MicroRNAs in cancer: personalizing diagnosis and therapy.

Nana-Sinkam SP, Fabbri M, Croce CM.

Ann N Y Acad Sci. 2010 Oct;1210:25-33. doi: 10.1111/j.1749-6632.2010.05822.x.

PMID:
20973796
20.

Personalized medicine using DNA biomarkers: a review.

Ziegler A, Koch A, Krockenberger K, Grosshennig A.

Hum Genet. 2012 Oct;131(10):1627-38. doi: 10.1007/s00439-012-1188-9. Review.

Items per page

Supplemental Content

Support Center